NCT00564200 - MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2014

Study Completion Date

October 31, 2014

Conditions

Multiple Myeloma

Interventions

DRUG

Bortezomib

"PREACONDICIONAMIENTO:~* 2 cycles of 21 days : Velcade days: 1, 4, 8 and 11~* 1 cycle of 13 days : Velcade days 1, 4, 8 and 11~ACONDICIONAMIENTO:~\- Day -2: Velcade~POSTRANSPLANTATION:~* 2 cycles of 21 days : Velcade days 1, 8 and 15~* 5 cycles of 56 days : Velcade days 1, 8 and 15"

DRUG

dexamethasone

"PREACONDICIONAMIENTO:~\- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11"

DRUG

Fludarabine

"ACONDICIONAMIENTO:~\- Days -9 al -5: Fludarabine"

DRUG

Melphalan

"ACONDICIONAMIENTO:~\- Days -4 and -3: Melphalan."

Trial Locations (10)

Unknown

H. Clinic I Provincial, Barcelona

H. de la Santa Creu I Sant Pau, Barcelona

Instituto Catalán de Oncología, Barcelona

H. de Jerez, Jerez de la Frontera

H. 12 de Octubre, Madrid

H. Univ. Gregorio Marañón, Madrid

H. Univ. La Princesa, Madrid

H. Univ. Morales Meseguer, Murcia

H. Univ. Son Dureta, Palma de Mallorca

H. Univ. de Salamanca, Salamanca

All Listed Sponsors

lead

PETHEMA Foundation

OTHER